In Q1 2025, around 13 million packages of cholesterol and triglyceride regulating preparations (C10A by EphMRA classification) ​​worth 7.02 billion rubles were sold on Russian pharmaceutical retail market. Among the 15 best-selling pharmacotherapeutic groups in monetary terms, lipid-regulating drugs ranked second after hepatoprotectors and lipotropics. The sales grew 22.8% in monetary and 9.7% in physical terms from January–March 2024.

According to RNC Pharma’s Audit of Pharmaceutical Drug Retail Sales in Russia database, Russian manufacturers accounted for 54.4% of the sales of lipid-regulating preparations in monetary and for around 77.8% in physical terms in Q1 2025. Interestingly, the share of Russian-made products has been consistently growing over the past three years. Back in 2022, Russian manufacturers accounted for 47.9% of the sales in rubles and 73.4% in packages.

Yet, the growth rates of the top three brands were only average in the analyzed period. The share of the Russian company Severnaya Zvezda was 12.1%, with growth rates of 16%. Severnaya Zvezda is followed by KRKA, with a share of 11.4% and growth rates of 9.4%. AstraZeneca rounds out the top three, accounting for 9.7% of the sales, with growth rates of 15%. Two Russian manufacturers, Velpharm and Ozon Pharm, had the highest growth rates—the sales of Velpharm products rose 2.7 times against Q1 2024, while those of Ozon Pharm went up 96%.

Generic atorvastatin and rosuvastatin medicines topped the ranking, accounting for 45.5% of the sales in monetary terms. While generics of 24 manufacturers were on the market, certain companies had better sales. The growth rates for both drugs were different—in particular, the sales of rosuvastatin went up 30% from January–March 2025. Non-branded ezetimibe had the best growth rates in monetary terms—its sales rose 2.3 times against Q1 2025, while the sales of branded medicines lagged behind, although the growth rates were still above average. Livazo by Recordati ranked second with growth rates of 62%. Ezetrol by Organon had high growth rates of 30% as well. The sales of Torvacard by Sanofi, however, went down 6%, due to the obvious abundance of alternatives.

Fig. Top 15 brands of lipid-regulating preparations on the Russian retail market in Q1 2025